Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, i… Read more
Reviva Pharmaceuticals Holdings Inc. (RVPH) - Net Assets
Latest net assets as of September 2025: $4.55 Million USD
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has net assets worth $4.55 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.33 Million) and total liabilities ($9.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.55 Million |
| % of Total Assets | 31.74% |
| Annual Growth Rate | -51.05% |
| 5-Year Change | -85.13% |
| 10-Year Change | N/A |
| Growth Volatility | 201.59 |
Reviva Pharmaceuticals Holdings Inc. - Net Assets Trend (2018–2024)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Reviva Pharmaceuticals Holdings Inc. (2018–2024)
The table below shows the annual net assets of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $812.57K | -85.79% |
| 2023-12-31 | $5.72 Million | -31.87% |
| 2022-12-31 | $8.39 Million | -70.74% |
| 2021-12-31 | $28.69 Million | +424.84% |
| 2020-12-31 | $5.47 Million | +180.24% |
| 2019-12-31 | $-6.81 Million | -111.51% |
| 2018-12-31 | $59.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Reviva Pharmaceuticals Holdings Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10974634500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.66K | 0.57% |
| Other Components | $165.08 Million | 20315.86% |
| Total Equity | $812.57K | 100.00% |
Reviva Pharmaceuticals Holdings Inc. Competitors by Market Cap
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sparebank 68 Grader Nord
OL:SB68
|
$30.45 Million |
|
Shuz Tung Machinery Industrial Co., Ltd.
TWO:4537
|
$30.45 Million |
|
Royal Orchid Hotels Limited
NSE:ROHLTD
|
$30.46 Million |
|
Silver X Mining Corp
OTCQB:AGXPF
|
$30.46 Million |
|
Uangel
KO:072130
|
$30.45 Million |
|
Mildex Optical
TWO:4729
|
$30.44 Million |
|
CATER. INTL SVCS-CISINH.
F:8WG
|
$30.44 Million |
|
Societe d Exploration Miniere Vior Inc
V:VIO
|
$30.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Reviva Pharmaceuticals Holdings Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,718,716 to 812,572, a change of -4,906,144 (-85.8%).
- Net loss of 29,918,802 reduced equity.
- New share issuances of 23,194,488 increased equity.
- Other factors increased equity by 1,818,170.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.92 Million | -3681.99% |
| Share Issuances | $23.19 Million | +2854.45% |
| Other Changes | $1.82 Million | +223.75% |
| Total Change | $- | -85.79% |
Book Value vs Market Value Analysis
This analysis compares Reviva Pharmaceuticals Holdings Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 94.64x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-2.46 | $2.32 | x |
| 2020-12-31 | $1.79 | $2.32 | x |
| 2021-12-31 | $1.94 | $2.32 | x |
| 2022-12-31 | $0.43 | $2.32 | x |
| 2023-12-31 | $0.24 | $2.32 | x |
| 2024-12-31 | $0.02 | $2.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Reviva Pharmaceuticals Holdings Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3681.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 19.08x
- Recent ROE (-3681.99%) is below the historical average (-792.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-165.69K |
| 2020 | -69.22% | 0.00% | 0.00x | 1.60x | $-4.33 Million |
| 2021 | -29.71% | 0.00% | 0.00x | 1.09x | $-11.39 Million |
| 2022 | -289.95% | 0.00% | 0.00x | 2.25x | $-25.18 Million |
| 2023 | -686.53% | 0.00% | 0.00x | 4.14x | $-39.83 Million |
| 2024 | -3681.99% | 0.00% | 0.00x | 19.08x | $-30.00 Million |
Industry Comparison
This section compares Reviva Pharmaceuticals Holdings Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Reviva Pharmaceuticals Holdings Inc. (RVPH) | $4.55 Million | 0.00% | 2.15x | $30.45 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |